UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price objective suggests a potential upside of 132.99% from the company’s previous close.

URGN has been the topic of several other research reports. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Stock Up 8.1 %

Shares of URGN traded up $0.80 during midday trading on Wednesday, reaching $10.73. 128,287 shares of the stock were exchanged, compared to its average volume of 442,661. UroGen Pharma has a 52 week low of $9.78 and a 52 week high of $20.70. The company’s 50 day moving average is $11.50 and its two-hundred day moving average is $13.21. The company has a market capitalization of $251.66 million, a P/E ratio of -3.41 and a beta of 1.09. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the previous year, the business earned ($0.68) earnings per share. On average, sell-side analysts anticipate that UroGen Pharma will post -3.1 earnings per share for the current year.

Institutional Investors Weigh In On UroGen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of UroGen Pharma during the second quarter worth about $719,000. Millennium Management LLC raised its position in UroGen Pharma by 2,672.0% during the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after buying an additional 1,119,019 shares during the last quarter. Barclays PLC lifted its stake in UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after acquiring an additional 48,040 shares during the period. Point72 Asset Management L.P. lifted its stake in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares during the period. Finally, Wesbanco Bank Inc. purchased a new stake in shares of UroGen Pharma in the 3rd quarter valued at $945,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.